Comparison of the efficacy of first-/second-generation EGFR-tyrosine kinase inhibitors and osimertinib for EGFR-mutant lung cancer with negative or low PD-L1 expression

Minehiko Inomata*, Shuhei Minatoyama, Naoki Takata, Kana Hayashi, Takahiro Hirai, Zenta Seto, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Comparison of the efficacy of first-/second-generation EGFR-tyrosine kinase inhibitors and osimertinib for EGFR-mutant lung cancer with negative or low PD-L1 expression'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science